Resultado de búsqueda
Immunotherapy can cause rare but serious problems afecting the nervous system, heart, kidneys, eyes, and pancreas. Symptoms of a nervous system side efect can include muscle weakness, confusion, headaches, sensitivity to light, changes in behavior, and seizures. Heart and blood vessel side efects are rare but serious.
Aquí nos gustaría mostrarte una descripción, pero el sitio web que estás mirando no lo permite.
23 de feb. de 2021 · Common adverse reactions to pregabalin and gabapentin include dizziness, drowsiness, and somnolence; pregabalin is also more frequently associated with weight gain . Similar to tricyclic antidepressant, gabapentin and pregabalin may be considered for CIPN treatment based on the limited therapeutic options and the demonstrated efficacy of these agents in other neuropathic pain conditions [ 6 ].
22 de may. de 2023 · Cisplatin is a medication used to manage and treat solid tumors and hematologic malignancies. It is in the alkylating agent class of cytotoxic medications. This activity reviews the indications, action, and contraindications for cisplatinum as a valuable agent in treating malignancy. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off ...
11 de mar. de 2019 · The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists ...
29 de may. de 2021 · Patients received lurbinectedin 3.2 mg/m 2 as an intravenous infusion every 3 weeks, resulting in a response rate of 35.2% and a disease control rate of 68.6%. The response rate was 45% among those with > 90 days chemotherapy free interval (CTFI) and 22% in the resistant group (CTFI < 90 days). The median overall survival was 9.3 months.
1 de jun. de 2023 · With the increased use of immune checkpoint inhibition (ICI) comes an increase in the number of patients being treated for immune-related adverse events (irAEs). At the NCCN 2023 Annual Conference, presenters discussed 3 different types of irAEs, namely immune-mediated pneumonitis, major adverse cardiac events including myocarditis and myositis/myasthenia gravis overlap syndrome, and oral ...
